KemPharm Inc (NASDAQ:KMPH) has been assigned an average rating of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $10.25.
A number of research firms recently commented on KMPH. ValuEngine raised shares of KemPharm from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research cut shares of KemPharm from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. Canaccord Genuity set a $11.00 price target on shares of KemPharm and gave the stock a “buy” rating in a report on Friday, February 23rd. Oppenheimer set a $13.00 price target on shares of KemPharm and gave the stock a “buy” rating in a report on Sunday, February 25th. Finally, Royal Bank of Canada set a $9.00 price target on shares of KemPharm and gave the stock a “buy” rating in a report on Tuesday, January 16th.
Several large investors have recently bought and sold shares of KMPH. C WorldWide Group Holding A S raised its holdings in shares of KemPharm by 14.1% in the 3rd quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after purchasing an additional 53,829 shares during the period. Victory Capital Management Inc. raised its holdings in KemPharm by 26.7% during the 4th quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after acquiring an additional 34,114 shares during the period. Finally, Alyeska Investment Group L.P. raised its holdings in KemPharm by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after acquiring an additional 17,721 shares during the period. 36.56% of the stock is currently owned by institutional investors.
KemPharm (NASDAQ:KMPH) traded down $0.05 during trading hours on Friday, hitting $6.65. 46,161 shares of the company were exchanged, compared to its average volume of 235,714. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56. The company has a market cap of $97.47 and a PE ratio of -2.28. KemPharm has a 52 week low of $2.45 and a 52 week high of $7.45.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/kempharm-inc-kmph-given-consensus-rating-of-buy-by-analysts.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.